ABEONA THERAPEUTICS INC. Total Long-Term Debt
ABEONA THERAPEUTICS INC. (ABEO) had Total Long-Term Debt of $14.99 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-08-13
- 2026-06-30: Long-term Debt $14.99M.
- 2026-03-31: Long-term Debt $18.09M.
- 2025-12-31: Long-term Debt $20.04M.
- 2025-09-30: Long-term Debt $19.75M.
| Period end | Long-term Debt |
|---|---|
| 2026-06-30 | $14.99M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $18.09M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $20.04M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $19.75M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $19.56M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $19.29M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $18.96M 10-K · filed 2026-03-17 |
| 2024-09-30 | $18.65M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $18.36M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $18.08M 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |